Activating ligands of both IGF-1R and ErbB3 promote ovarian cancer cell proliferation and pro-survival signaling activation, whereas dual blocking of IGF-1R and ErbB3 enhances the efficacy of relevant chemotherapies. This evidence concerns the gene ERBB3 and ovarian cancer.